ACME Laboratories (DHA:ACMELAB) Other Current Receivables: BDT25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
91 GF Score
Price BDT84.30
GF Value BDT126.09
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is ACME Laboratories Other Current Receivables?

ACME Laboratories DHA:ACMELAB 91 Other Current Receivables is BDT25 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 91/100 and a GF Value™ of BDT126.09 (Possible Value Trap). The stock has 8 warning signs investors should review.

ACME Laboratories's Other Current Receivables for the quarter that ended in Mar. 2026 was BDT25 Mil.

ACME Laboratories's quarterly Other Current Receivables increased from Sep. 2025 (BDT120.11 Mil) to Dec. 2025 (BDT129.79 Mil) but then stayed the same from Dec. 2025 (BDT129.79 Mil) to Mar. 2026 (BDT24.82 Mil).

ACME Laboratories's annual Other Current Receivables increased from Jun. 2022 (BDT19.81 Mil) to Jun. 2023 (BDT19.89 Mil) and increased from Jun. 2023 (BDT19.89 Mil) to Jun. 2024 (BDT20.13 Mil).

ACME Laboratories Other Current Receivables Related Terms

ACME Laboratories Other Current Receivables Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Other Current Receivables Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 19.73 19.93 19.81 19.89 20.13

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.12 84.63 120.11 129.79 24.82
DHA:ACMELAB
91GF Score
ACME Laboratories Ltd DHA:ACMELAB
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of BDT25 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Other Current Receivables of BDT25 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ACME Laboratories and its competitors.
Is ACME Laboratories' Other Current Receivables too high?
ACME Laboratories' current Other Current Receivables is BDT25 Mil. Overall, ACME Laboratories has a GF Score™ of 91/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Other Current Receivables compare to ZTS and UTHR?
ACME Laboratories' Other Current Receivables of BDT25 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current Other Current Receivables is BDT25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.09, compared to a current price of BDT84.30 — trading 33.1% below its estimated fair value. The current Other Current Receivables is BDT25 Mil. ACME Laboratories' overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Other Current Receivables is BDT25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT84.30 is trading 33.1% below its estimated GF Value™ of BDT126.09. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Other Current Receivables: BDT25 Mil
  • GF Value™: BDT126.09 vs. price of BDT84.30 (33.1% below fair value)
  • GF Score™: 91/100 with 8 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
91GF Score

Get the complete analysis for DHA:ACMELAB

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT84.30
Price
BDT126.09
GF Value